LBRX peer analysis
LB Pharmaceuticals (LBRX) against its competitors: price, today's move, 1-year return and market value side by side.
LBRX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals | $21.23 | -0.05% | -2.97% | $3.70B |
| ANRO Alto Neuroscience | $25.03 | 14.45% | 94.75% | – |
| DFTX Definium Therapeutics | $33.42 | 10.08% | – | – |
| DNLI Denali Therapeutics | $20.16 | 2.23% | 32.07% | $3.36B |
| GHRS GH Research | $18.61 | 0.92% | 36.59% | – |
| MPLT MapLight Therapeutics | $7.60 | 22.19% | -61.82% | – |
| NERV Minerva Neurosciences | $2.30 | -10.51% | -29.97% | $122.71M |
| NMRA Neumora Therapeutics | $0.49 | -13.96% | -79.71% | – |
| RAPP Rapport Therapeutics | $24.44 | 3.04% | -11.07% | – |
| SPTX Seaport Therapeutics | $21.50 | 5.44% | – | – |
| LBRX LB Pharmaceuticals | $42.50 | 11.58% | 134.06% | – |
- LBRX's peers: ACAD (Acadia Pharmaceuticals), ANRO (Alto Neuroscience), DFTX (Definium Therapeutics), DNLI (Denali Therapeutics), GHRS (GH Research), MPLT (MapLight Therapeutics), NERV (Minerva Neurosciences), NMRA (Neumora Therapeutics).
Updated 2026-11-07 11:53 UTC